Repaglinide insulin secretagogues

AG-EE 623 ZW - AG-EE 388 - Prandin - GlucoNorm - NovoNorm - AG-EE 388 ZW - repa-glinide

Diabetes type 2

All type of patients:  13 trials  - Moses - Lund - Chuang - Landgraf - Marbury - Wolffenbuttel - Madsbad - Raskin - Raskin - Raskin - Landin-Olsson - Goldberg - Jovanovic

repaglinide vs control (add on MET)

No demonstrated result

repaglinide vs glibenclamide

No demonstrated result

repaglinide vs glipizide

No demonstrated result

repaglinide vs metformin

No demonstrated result

repaglinide vs on top pioglitazone

No demonstrated result

repaglinide vs on top rosiglitazone

No demonstrated result

repaglinide vs on top troglitazone

No demonstrated result

repaglinide vs placebo

No demonstrated result

repaglinide vs placebo (on top bedtime NPH-insulin)

No demonstrated result

See more clinical conditions

All types of patients:  13 trials  - Moses - Lund - Chuang - Landgraf - Marbury - Wolffenbuttel - Madsbad - Raskin - Raskin - Raskin - Landin-Olsson - Goldberg - Jovanovic

repaglinide vs control (add on MET)

No demonstrated result

repaglinide vs glibenclamide

No demonstrated result

repaglinide vs glipizide

No demonstrated result

repaglinide vs metformin

No demonstrated result

repaglinide vs on top pioglitazone

No demonstrated result

repaglinide vs on top rosiglitazone

No demonstrated result

repaglinide vs on top troglitazone

No demonstrated result

repaglinide vs placebo

No demonstrated result

repaglinide vs placebo (on top bedtime NPH-insulin)

No demonstrated result

Patients inadequately controlled on metformin:  1 trials  - Moses

repaglinide vs control (add on MET)

No demonstrated result

Patients inadequately controlled on monotherapy :  1 trials  - Moses

repaglinide vs control (add on MET)

No demonstrated result